Review



case human prostate cancer tma  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Novus Biologicals case human prostate cancer tma
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Case Human Prostate Cancer Tma, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 20 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/case human prostate cancer tma/product/Novus Biologicals
    Average 90 stars, based on 20 article reviews
    case human prostate cancer tma - by Bioz Stars, 2026-04
    90/100 stars

    Images

    1) Product Images from "Siglec-engaging immunosuppressive sialoglycans are upregulated in prostate cancer and are targetable to suppress bone metastasis"

    Article Title: Siglec-engaging immunosuppressive sialoglycans are upregulated in prostate cancer and are targetable to suppress bone metastasis

    Journal: bioRxiv

    doi: 10.1101/2025.11.12.687981

    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a TMA comprising 51 prostate tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Figure Legend Snippet: ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a TMA comprising 51 prostate tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.

    Techniques Used: Immunohistochemistry, Staining

    ( A ) HYDRA immunohistochemistry analysis of ligands for Siglec-3, Siglec-7, and Siglec-9 in untreated primary prostate tissue compared to metastatic castrate resistant cancer (CRPC) growing in bone suggests all three sialoglycan ligands are increased in treatment resistant metastatic tumours relative to untreated primary prostate cancer tissues (n=205, unpaired t tests, HYDRA-3 p <0.0001, HYDRA-7 p<0.0001, HYDRA-9 p<0.0001). Scale bar is 200□µm. ( B ) Analysis of Siglec-7 ligands in a TMA generated by the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project . HYDRA-7 immunohistochemistry shows Siglec-7 ligands are expressed at similar levels in untreated / hormone naïve primary prostate tumours compared to therapy resistant (CRPC) tissues (n=161, unpaired t test, p=0.0904). Scale bar is 200□µm. ( C ) HYDRA immunohistochemistry analysis of Siglec-7 ligands in a TMA containing primary prostate tissue and rapid autopsy tissue obtained from lethal visceral and bone metastatic tumours . HYDRA-7 Histoscores were significantly higher in lethal bone metastatic prostate tumours compared to unmatched primary prostate tumours (n=238, Welsh’s ANOVA test, p<0.0001). The levels of Siglec-7 ligands were significantly higher in prostate derived tumours growing in bone compared to matched visceral tumour tissue from the same patient (n=100, paired t test, p<0.0001). Scale bar is 200□µm. ( D ) HYDRA-7 immunohistochemistry analysis of Siglec-7 ligands in a 100-case prostate cancer TMA. Stratification of patients based on high and low Siglec-7 ligand levels shows patients with high HYDRA-7 levels (defined as the top 50 th percentile of expression) had significantly poorer survival rates compared to patients with low HYDRA-7 levels (defined as the bottom 50 th percentile of expression) (n=100, Kaplan-Meier regression model, p= 0.0041). Scale bar is 200□µm.
    Figure Legend Snippet: ( A ) HYDRA immunohistochemistry analysis of ligands for Siglec-3, Siglec-7, and Siglec-9 in untreated primary prostate tissue compared to metastatic castrate resistant cancer (CRPC) growing in bone suggests all three sialoglycan ligands are increased in treatment resistant metastatic tumours relative to untreated primary prostate cancer tissues (n=205, unpaired t tests, HYDRA-3 p <0.0001, HYDRA-7 p<0.0001, HYDRA-9 p<0.0001). Scale bar is 200□µm. ( B ) Analysis of Siglec-7 ligands in a TMA generated by the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project . HYDRA-7 immunohistochemistry shows Siglec-7 ligands are expressed at similar levels in untreated / hormone naïve primary prostate tumours compared to therapy resistant (CRPC) tissues (n=161, unpaired t test, p=0.0904). Scale bar is 200□µm. ( C ) HYDRA immunohistochemistry analysis of Siglec-7 ligands in a TMA containing primary prostate tissue and rapid autopsy tissue obtained from lethal visceral and bone metastatic tumours . HYDRA-7 Histoscores were significantly higher in lethal bone metastatic prostate tumours compared to unmatched primary prostate tumours (n=238, Welsh’s ANOVA test, p<0.0001). The levels of Siglec-7 ligands were significantly higher in prostate derived tumours growing in bone compared to matched visceral tumour tissue from the same patient (n=100, paired t test, p<0.0001). Scale bar is 200□µm. ( D ) HYDRA-7 immunohistochemistry analysis of Siglec-7 ligands in a 100-case prostate cancer TMA. Stratification of patients based on high and low Siglec-7 ligand levels shows patients with high HYDRA-7 levels (defined as the top 50 th percentile of expression) had significantly poorer survival rates compared to patients with low HYDRA-7 levels (defined as the bottom 50 th percentile of expression) (n=100, Kaplan-Meier regression model, p= 0.0041). Scale bar is 200□µm.

    Techniques Used: Immunohistochemistry, Generated, Microarray, Derivative Assay, Expressing



    Similar Products

    90
    Novus Biologicals case human prostate cancer tma
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Case Human Prostate Cancer Tma, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/case human prostate cancer tma/product/Novus Biologicals
    Average 90 stars, based on 1 article reviews
    case human prostate cancer tma - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    92
    U.S Biomax Inc human multiple prostate cancer tissue microarrays tma pr483
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Human Multiple Prostate Cancer Tissue Microarrays Tma Pr483, supplied by U.S Biomax Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human multiple prostate cancer tissue microarrays tma pr483/product/U.S Biomax Inc
    Average 92 stars, based on 1 article reviews
    human multiple prostate cancer tissue microarrays tma pr483 - by Bioz Stars, 2026-04
    92/100 stars
      Buy from Supplier

    90
    Novus Biologicals human prostate cancer tissue microarray tma
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Human Prostate Cancer Tissue Microarray Tma, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human prostate cancer tissue microarray tma/product/Novus Biologicals
    Average 90 stars, based on 1 article reviews
    human prostate cancer tissue microarray tma - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    Novus Biologicals histopathology human prostate cancer tissue microarray tma
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Histopathology Human Prostate Cancer Tissue Microarray Tma, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/histopathology human prostate cancer tissue microarray tma/product/Novus Biologicals
    Average 90 stars, based on 1 article reviews
    histopathology human prostate cancer tissue microarray tma - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    92
    U.S Biomax Inc immunohistochemistry human prostate cancer tissue microarray tma
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Immunohistochemistry Human Prostate Cancer Tissue Microarray Tma, supplied by U.S Biomax Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/immunohistochemistry human prostate cancer tissue microarray tma/product/U.S Biomax Inc
    Average 92 stars, based on 1 article reviews
    immunohistochemistry human prostate cancer tissue microarray tma - by Bioz Stars, 2026-04
    92/100 stars
      Buy from Supplier

    92
    U.S Biomax Inc human prostate cancer tissue microarray tma
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Human Prostate Cancer Tissue Microarray Tma, supplied by U.S Biomax Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human prostate cancer tissue microarray tma/product/U.S Biomax Inc
    Average 92 stars, based on 1 article reviews
    human prostate cancer tissue microarray tma - by Bioz Stars, 2026-04
    92/100 stars
      Buy from Supplier

    92
    U.S Biomax Inc analysis human prostate cancer tissue microarray tma pr242b
    A. Representative images (10× with 40× insert) of normal adjacent tissues (NAT) and adenocarcinomas. A tissue micro array (TMA) purchased from US Biomax, Inc. <t>(PR242b)</t> was stained for pseudouridine and imaged at 10X and 40X. Cores with Gleason 3+3, 4+3 and 5+4 were used for representative images. Staining is primarily localized to the cytoplasm of glandular cells with negligible staining of the gland cells belonging to normal adjacent tissues (NATs). B. Plot of H-scores of normal adjacent tissues and adenocarcinomas. Each individual core was evaluated by an in-house pathologist for the presence of cancer, and given an H-score. The final H-score is the summation of (1+i)pi where i is the intensity score [0 (lowest)1+, 2+, 3+, 4+(highest)] and pi is the percent of the cells with that intensity. The p-value was calculated using a two-tailed unpaired t-test in Prism, where an alpha value of 0.05 was considered significant.
    Analysis Human Prostate Cancer Tissue Microarray Tma Pr242b, supplied by U.S Biomax Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/analysis human prostate cancer tissue microarray tma pr242b/product/U.S Biomax Inc
    Average 92 stars, based on 1 article reviews
    analysis human prostate cancer tissue microarray tma pr242b - by Bioz Stars, 2026-04
    92/100 stars
      Buy from Supplier

    92
    U.S Biomax Inc human prostate cancer tissue microarray tma pr242b
    A. Representative images (10× with 40× insert) of normal adjacent tissues (NAT) and adenocarcinomas. A tissue micro array (TMA) purchased from US Biomax, Inc. <t>(PR242b)</t> was stained for pseudouridine and imaged at 10X and 40X. Cores with Gleason 3+3, 4+3 and 5+4 were used for representative images. Staining is primarily localized to the cytoplasm of glandular cells with negligible staining of the gland cells belonging to normal adjacent tissues (NATs). B. Plot of H-scores of normal adjacent tissues and adenocarcinomas. Each individual core was evaluated by an in-house pathologist for the presence of cancer, and given an H-score. The final H-score is the summation of (1+i)pi where i is the intensity score [0 (lowest)1+, 2+, 3+, 4+(highest)] and pi is the percent of the cells with that intensity. The p-value was calculated using a two-tailed unpaired t-test in Prism, where an alpha value of 0.05 was considered significant.
    Human Prostate Cancer Tissue Microarray Tma Pr242b, supplied by U.S Biomax Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human prostate cancer tissue microarray tma pr242b/product/U.S Biomax Inc
    Average 92 stars, based on 1 article reviews
    human prostate cancer tissue microarray tma pr242b - by Bioz Stars, 2026-04
    92/100 stars
      Buy from Supplier

    90
    Novus Biologicals prostate cancer tissue microarray tma
    A. Representative images (10× with 40× insert) of normal adjacent tissues (NAT) and adenocarcinomas. A tissue micro array (TMA) purchased from US Biomax, Inc. <t>(PR242b)</t> was stained for pseudouridine and imaged at 10X and 40X. Cores with Gleason 3+3, 4+3 and 5+4 were used for representative images. Staining is primarily localized to the cytoplasm of glandular cells with negligible staining of the gland cells belonging to normal adjacent tissues (NATs). B. Plot of H-scores of normal adjacent tissues and adenocarcinomas. Each individual core was evaluated by an in-house pathologist for the presence of cancer, and given an H-score. The final H-score is the summation of (1+i)pi where i is the intensity score [0 (lowest)1+, 2+, 3+, 4+(highest)] and pi is the percent of the cells with that intensity. The p-value was calculated using a two-tailed unpaired t-test in Prism, where an alpha value of 0.05 was considered significant.
    Prostate Cancer Tissue Microarray Tma, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/prostate cancer tissue microarray tma/product/Novus Biologicals
    Average 90 stars, based on 1 article reviews
    prostate cancer tissue microarray tma - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a TMA comprising 51 prostate tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.

    Journal: bioRxiv

    Article Title: Siglec-engaging immunosuppressive sialoglycans are upregulated in prostate cancer and are targetable to suppress bone metastasis

    doi: 10.1101/2025.11.12.687981

    Figure Lengend Snippet: ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a TMA comprising 51 prostate tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.

    Article Snippet: TMA cohort 1 : 40 case human prostate cancer TMA was purchased from Novus Bio (NBP2-30169).

    Techniques: Immunohistochemistry, Staining

    ( A ) HYDRA immunohistochemistry analysis of ligands for Siglec-3, Siglec-7, and Siglec-9 in untreated primary prostate tissue compared to metastatic castrate resistant cancer (CRPC) growing in bone suggests all three sialoglycan ligands are increased in treatment resistant metastatic tumours relative to untreated primary prostate cancer tissues (n=205, unpaired t tests, HYDRA-3 p <0.0001, HYDRA-7 p<0.0001, HYDRA-9 p<0.0001). Scale bar is 200□µm. ( B ) Analysis of Siglec-7 ligands in a TMA generated by the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project . HYDRA-7 immunohistochemistry shows Siglec-7 ligands are expressed at similar levels in untreated / hormone naïve primary prostate tumours compared to therapy resistant (CRPC) tissues (n=161, unpaired t test, p=0.0904). Scale bar is 200□µm. ( C ) HYDRA immunohistochemistry analysis of Siglec-7 ligands in a TMA containing primary prostate tissue and rapid autopsy tissue obtained from lethal visceral and bone metastatic tumours . HYDRA-7 Histoscores were significantly higher in lethal bone metastatic prostate tumours compared to unmatched primary prostate tumours (n=238, Welsh’s ANOVA test, p<0.0001). The levels of Siglec-7 ligands were significantly higher in prostate derived tumours growing in bone compared to matched visceral tumour tissue from the same patient (n=100, paired t test, p<0.0001). Scale bar is 200□µm. ( D ) HYDRA-7 immunohistochemistry analysis of Siglec-7 ligands in a 100-case prostate cancer TMA. Stratification of patients based on high and low Siglec-7 ligand levels shows patients with high HYDRA-7 levels (defined as the top 50 th percentile of expression) had significantly poorer survival rates compared to patients with low HYDRA-7 levels (defined as the bottom 50 th percentile of expression) (n=100, Kaplan-Meier regression model, p= 0.0041). Scale bar is 200□µm.

    Journal: bioRxiv

    Article Title: Siglec-engaging immunosuppressive sialoglycans are upregulated in prostate cancer and are targetable to suppress bone metastasis

    doi: 10.1101/2025.11.12.687981

    Figure Lengend Snippet: ( A ) HYDRA immunohistochemistry analysis of ligands for Siglec-3, Siglec-7, and Siglec-9 in untreated primary prostate tissue compared to metastatic castrate resistant cancer (CRPC) growing in bone suggests all three sialoglycan ligands are increased in treatment resistant metastatic tumours relative to untreated primary prostate cancer tissues (n=205, unpaired t tests, HYDRA-3 p <0.0001, HYDRA-7 p<0.0001, HYDRA-9 p<0.0001). Scale bar is 200□µm. ( B ) Analysis of Siglec-7 ligands in a TMA generated by the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project . HYDRA-7 immunohistochemistry shows Siglec-7 ligands are expressed at similar levels in untreated / hormone naïve primary prostate tumours compared to therapy resistant (CRPC) tissues (n=161, unpaired t test, p=0.0904). Scale bar is 200□µm. ( C ) HYDRA immunohistochemistry analysis of Siglec-7 ligands in a TMA containing primary prostate tissue and rapid autopsy tissue obtained from lethal visceral and bone metastatic tumours . HYDRA-7 Histoscores were significantly higher in lethal bone metastatic prostate tumours compared to unmatched primary prostate tumours (n=238, Welsh’s ANOVA test, p<0.0001). The levels of Siglec-7 ligands were significantly higher in prostate derived tumours growing in bone compared to matched visceral tumour tissue from the same patient (n=100, paired t test, p<0.0001). Scale bar is 200□µm. ( D ) HYDRA-7 immunohistochemistry analysis of Siglec-7 ligands in a 100-case prostate cancer TMA. Stratification of patients based on high and low Siglec-7 ligand levels shows patients with high HYDRA-7 levels (defined as the top 50 th percentile of expression) had significantly poorer survival rates compared to patients with low HYDRA-7 levels (defined as the bottom 50 th percentile of expression) (n=100, Kaplan-Meier regression model, p= 0.0041). Scale bar is 200□µm.

    Article Snippet: TMA cohort 1 : 40 case human prostate cancer TMA was purchased from Novus Bio (NBP2-30169).

    Techniques: Immunohistochemistry, Generated, Microarray, Derivative Assay, Expressing

    A. Representative images (10× with 40× insert) of normal adjacent tissues (NAT) and adenocarcinomas. A tissue micro array (TMA) purchased from US Biomax, Inc. (PR242b) was stained for pseudouridine and imaged at 10X and 40X. Cores with Gleason 3+3, 4+3 and 5+4 were used for representative images. Staining is primarily localized to the cytoplasm of glandular cells with negligible staining of the gland cells belonging to normal adjacent tissues (NATs). B. Plot of H-scores of normal adjacent tissues and adenocarcinomas. Each individual core was evaluated by an in-house pathologist for the presence of cancer, and given an H-score. The final H-score is the summation of (1+i)pi where i is the intensity score [0 (lowest)1+, 2+, 3+, 4+(highest)] and pi is the percent of the cells with that intensity. The p-value was calculated using a two-tailed unpaired t-test in Prism, where an alpha value of 0.05 was considered significant.

    Journal: American Journal of Clinical and Experimental Urology

    Article Title: Predictive value of pseudouridine in prostate cancer

    doi:

    Figure Lengend Snippet: A. Representative images (10× with 40× insert) of normal adjacent tissues (NAT) and adenocarcinomas. A tissue micro array (TMA) purchased from US Biomax, Inc. (PR242b) was stained for pseudouridine and imaged at 10X and 40X. Cores with Gleason 3+3, 4+3 and 5+4 were used for representative images. Staining is primarily localized to the cytoplasm of glandular cells with negligible staining of the gland cells belonging to normal adjacent tissues (NATs). B. Plot of H-scores of normal adjacent tissues and adenocarcinomas. Each individual core was evaluated by an in-house pathologist for the presence of cancer, and given an H-score. The final H-score is the summation of (1+i)pi where i is the intensity score [0 (lowest)1+, 2+, 3+, 4+(highest)] and pi is the percent of the cells with that intensity. The p-value was calculated using a two-tailed unpaired t-test in Prism, where an alpha value of 0.05 was considered significant.

    Article Snippet: TMA immunohistochemistry and analysis Human prostate cancer tissue microarray (TMA) PR242b was purchased from US Biomax, Inc. (Derwood, MD, USA).

    Techniques: Microarray, Staining, Two Tailed Test

    A. Representative images (10× with 40× insert) of normal adjacent tissues (NAT) and adenocarcinomas. A tissue micro array (TMA) purchased from US Biomax, Inc. (PR242b) was stained for pseudouridine and imaged at 10X and 40X. Cores with Gleason 3+3, 4+3 and 5+4 were used for representative images. Staining is primarily localized to the cytoplasm of glandular cells with negligible staining of the gland cells belonging to normal adjacent tissues (NATs). B. Plot of H-scores of normal adjacent tissues and adenocarcinomas. Each individual core was evaluated by an in-house pathologist for the presence of cancer, and given an H-score. The final H-score is the summation of (1+i)pi where i is the intensity score [0 (lowest)1+, 2+, 3+, 4+(highest)] and pi is the percent of the cells with that intensity. The p-value was calculated using a two-tailed unpaired t-test in Prism, where an alpha value of 0.05 was considered significant.

    Journal: American Journal of Clinical and Experimental Urology

    Article Title: Predictive value of pseudouridine in prostate cancer

    doi:

    Figure Lengend Snippet: A. Representative images (10× with 40× insert) of normal adjacent tissues (NAT) and adenocarcinomas. A tissue micro array (TMA) purchased from US Biomax, Inc. (PR242b) was stained for pseudouridine and imaged at 10X and 40X. Cores with Gleason 3+3, 4+3 and 5+4 were used for representative images. Staining is primarily localized to the cytoplasm of glandular cells with negligible staining of the gland cells belonging to normal adjacent tissues (NATs). B. Plot of H-scores of normal adjacent tissues and adenocarcinomas. Each individual core was evaluated by an in-house pathologist for the presence of cancer, and given an H-score. The final H-score is the summation of (1+i)pi where i is the intensity score [0 (lowest)1+, 2+, 3+, 4+(highest)] and pi is the percent of the cells with that intensity. The p-value was calculated using a two-tailed unpaired t-test in Prism, where an alpha value of 0.05 was considered significant.

    Article Snippet: Human prostate cancer tissue microarray (TMA) PR242b was purchased from US Biomax, Inc. (Derwood, MD, USA).

    Techniques: Microarray, Staining, Two Tailed Test